Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in South Korea / NCT06388967
Recruiting Observational

Pancreatic Cancer Detection Consortium

NCT06388967 · tracked via the Priya Life Science South Korea tracker
Sponsor
City of Hope Medical Center
Phase
Observational
Started
2023-03-15
Last updated
2026-09-28

Condition(s) studied

Pancreatic CancerPancreatic CarcinomaPancreatic AdenocarcinomaPancreatic Ductal AdenocarcinomaPancreatic NeoplasmsPancreatic Cancer Stage IPancreatic Cancer StagePancreatic Cancer ResectablePancreatic Cancer Stage 0Pancreatic Cancer Stage IIPancreatic Cancer Stage IIIPancreatic Cancer, AdultPancreatic Cancer Non-resectable

Investigational drug(s) / intervention(s)

PANcreatic cancer Exosome Early detectiON (PANXEON)

PANcreatic cancer Exosome Early detectiON (PANXEON): This test will utilize quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) to quantify the expression levels of 5 cell-free and 8 exosome-miRNAs in plasma samples obtained from patients with pancreatic ductal adenocarcinoma and from individuals without it

Study summary

This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Histological diagnosis of pancreatic ductal adenocarcinoma, stages I-IV (TNM classification, 8th edition) * Received standard diagnostic and staging procedures as per local guidelines, and at least one sample was drawn before receiving any curative-intent treatment. * Imaging- or endoscopy-based proof of lack of pancreatic ductal adenocarcinoma at the time of sampling (Non-disease controls) Exclusion Criteria: * Lack of written informed consent.

Primary outcome measure(s)

  • Sensitivity — Through study completion, an average of 1 year
    True positive rate: the probability of a positive test result, conditioned on the individual truly being positive

Trial sites (13)

FacilityCityRegionStatus
Translational Genomics Research Institute Phoenix Arizona Recruiting
Honorhealth Scottsdale Arizona Terminated
City of Hope Medical Center Monrovia California Recruiting
Hoag Center Newport Beach California Terminated
OSF HealthCare Peoria Illinois Recruiting
Ochsner Medical Center Jefferson Louisiana Recruiting
Atlantic Health System Morristown New Jersey Recruiting
AHN Cancer Institute at Allegheny General Hospital Pittsburgh Pennsylvania Recruiting
Piedmont Medical Center Rock Hill South Carolina Recruiting
MultiCare Cancer Institute - Tacoma General Hospital Tacoma Washington Recruiting
Medical College of Wisconsin Milwaukee Wisconsin Recruiting
Nagoya University Nagoya Japan Recruiting
Asan Medical Center Seoul South Korea Recruiting

Other trials for the same condition

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 Recruiting
BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours Recruiting
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma Recruiting
Hydroxychloroquine and Chlorphenesin Carbamate in Combination With mFOLFIRINOX in Pancreatic Cancer Active, not recruiting
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06388967 on ClinicalTrials.gov ↗ ← All trials in South Korea